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Abstract
Background: An increased incidence of pneumonia in patients with chronic obstructive pulmonary disease (COPD)
under inhaled corticosteroid (ICS) therapy was noticed in previous studies. We performed a prospective study to
elucidate the risk factors for the development of pneumonia in this group of patients.
Methods: A prospective, non-randomized study with patients diagnosed as having COPD from 2007 to 2008
identified in the Far Eastern Memorial Hospital were recruited. We recorded data for all patients, including clinical
features and signs, demographic data, lung function status, and medications. Bio-markers such as C-reactive protein
(CRP) and placenta growth factor (PlGF) were checked at first diagnosis. Every acute exacerbation was also
recorded, especially pneumonia events, which were confirmed by chest radiography. Multivariate analysis was
performed with stepwise logistic regression for pneumonia risk factors.
Results: 274 patients were diagnosed as having COPD during the study period and 29 patients suffered from
pneumonia with a prevalence of 10.6%. The rate was significantly higher in patients with ICS therapy (20/125, 16%)
compared with those without ICS (9/149, 6%) (p = 0.02). We stratified ICS therapy into medium dose (500-999 ug/
day fluticasone equivalent, 71 patients) and high dose (1000 ug/day and higher fluticasone equivalent, 54 patients)
group. There was no statistical difference in the incidence of pneumonia between these two group (medium dose:
13/71, 18.3% vs. high dose: 7/54, 12.9%, p = 0.47). Multivariate analysis was performed to identify the risk factors for
developing pneumonia and included forced expiratory volume in one second (FEV1) less than 40% of predicted
(odds ratio (OR) 2.2, 95% confidence interval (CI): 1.1-6.9), ICS prescription ((OR) 2.4, 95% (CI): 1.3-8.7), the presence
of diabetes mellitus (DM) (OR 2.6, 95% CI: 1.2-9.4) and PlGF level over 40 pg/L (OR 4.1, 95% CI: 1.5-9.9).
Conclusion: ICS therapy in patients with COPD increased the risk of pneumonia. However, there was no
relationship between the incidence of pneumonia and dosage of ICS. Additionally, advanced COPD status, DM and
elevated PlGF level were independent risk factors for the development of pneumonia. PlGF would be a good novel
biomarker for predicting pneumonia.
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Chronic obstructive pulmonary disease (COPD) represents
an increasing burden worldwide. It has been estimated
that COPD will become the third most common cause of
death globally by the year 2030 [1]. COPD is a disease
characterized by progressive airflow limitation that is not
fully reversible, with symptoms of dyspnea, sputum pro-
duction and cough. The chronic airflow obstruction is
associated with an abnormal inflammatory response of the
lungs, and is caused primarily by cigarette smoking [2,3].
COPD is associated with significant morbidity and mortal-
ity and an increased risk of pneumonia [4,5]. Moreover,
patients with COPD who are hospitalized due to pneumo-
nia have been reported to be at higher risk of mortality
than patients without COPD [6,7].
Several studies have demonstrated that inhaled corti-
costeroids (ICS) therapy can reduce the frequency of
COPD exacerbations and improved health status [8-10].
The current Global Initiative for Chronic Obstructive
Pulmonary Disease (GOLD) guidelines suggests ICS
usage in symptomatic patients in severe or very severe
stage and repeated exacerbations [11].
ICS is prescribed to as many as 50% of patients with
COPD [12-14]. The TORCH (Towards a Revolution in
COPD Health) study [15] reported a 19% 3-year rate of
pneumonia in patients receiving fluticasone at 1000 μg/day,
corresponding to a significant 1.6- fold increase over pla-
cebo. Additionally, several randomized controlled reports
and meta-analysis studies have raised a possible safety issue
regarding the higher rate of pneumonia in ICS treatment
[16-19]. In contrast, other studies have reported different
results in which an increased incidence of pneumonia was
not seen with regard to ICS usage [20-23]. Therefore,
w h e t h e ro rn o tt h eu s eo fI C Si sa s s o c i a t e dw i t ha n
increased risk of pneumonia still needs to be elucidated.
N o r m a l l y ,P l G Fm R N Ai sp r e s e n tm o s ta b u n d a n t l yi n
the placenta, thyroid, and lungs [24], but the biologic func-
tion of PlGF in these tissues remains unclear. PlGF expres-
sion increases significantly in early gestation, peaks at
around 26-30 weeks, and decreased as term approaches
[25]. Recent studies have shown that PlGF can cause
emphysema when over-expressed in the mouse lung [26],
while knocking-out PlGF protected against the develop-
ment of elastase-induced emphysema [27]. Cheng and col-
leagues [28] have also reported that PlGF is released from
bronchial epithelial cells and potentially contributes to the
development of COPD. Recently, a meta-analysis study
showed that lower baseline lung function status was asso-
ciated with an increased incidence of pneumonia develop-
ment [29]. In addition, our previous studies revealed
that serum placenta growth factor (PlGF) levels were
inversely correlated to forced expiratory volume in one
second (FEV1) in COPD, [28] and that PlGF was a good
biomarker for predicting lung function and elevated levels
in sepsis [30]. Additionally, C-reactive protein (CRP) has
also been shown to be an important biomarker for sys-
temic inflammation in COPD [31,32]. Therefore, we con-
ducted a prospective study with the aim of assessing
whether ICS usage in patients with COPD increased the
rate of pneumonia, and whether PlGF and CRP could pre-
dict the development of pneumonia in patients with
COPD using ICS.
Methods
Source of Data
This report utilized a prospective, non-randomized study
from the Far Eastern Memorial Hospital. COPD was diag-
nosed on the basis of history, chest X-ray findings, physical
examination, and spirometric data, according to the Amer-
ican Thoracic Society guidelines [11]. Inclusion criteria for
COPD included: chronic airway symptoms and signs such
as coughing, breathlessness, wheezing and chronic airway
obstruction, which was defined as (1) FEV1/FVC less than
70% and (2) FEV1 less than 80% of the predicted value via
spirometric data; and FEV1 reversibility after inhalation of
200 μg salbutamol of less than 12% of pre- bronchodilator
FEV1. Subjects were excluded if they had a history of
asthma (reversibility of airflow obstruction) or malignant
lung disease. The follow-up time of the study was two
years.
Inhaled Corticosteroid Exposure
The ICS included inhaled beclomethasone, budesonide,
and fluticasone, whether dispensed alone or in a combina-
tion inhaler with an inhaled beta-agonist. The prescription
of ICS and other medications was determined by physi-
cians according to patients’ clinical status and lung func-
tion severity. The estimation of equivalence was used on
the basis of relative topical potency and what experts con-
sider to comparable doses according to the National
Asthma Education and Prevention Program Expert Panel
report 2 [23] and the Canadian asthma consensus state-
ment [24]. Accordingly, the equivalent doses for inhaled
corticosteroids were beclomethasone 100 μg, budesonide
80 μg and fluticasone 50 μg. All doses were converted to
fluticasone equivalents and categorized according to
defined daily doses of the most recent prescription as high
(fluticasone 1000 μg/d or more), and medium (fluticasone,
500-999 μg/d) and no ICS use.
Acute exacerbation of COPD was defined when a
patient presented with at least two of the following major
symptoms (increased dyspnea, increased sputum puru-
lence, increased sputum volume) or one major and one
minor symptom (nasal discharge/congestion, wheeze, sore
throat, cough) for at least two consecutive days [25,26]. All
chest radiographs were assessed by the investigators
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there was radiographic evidence of pulmonary infection
(new infiltrates and consolidation on the chest roentgen-
ography) and combined with the symptoms of acute
exacerbation. If chest radiographs were not available,
patients were excluded from our study.
Collection of peripheral blood & quantification of serum
biomarker levels
Peripheral blood from patients with COPD at initial diag-
nosis was collected in heparinized syringes and centrifuged
within 15 minutes of collection. The plasma was kept at
-70°C until analysis by a technician who was blinded to
the patients’ condition. The levels of PlGF in the serum
were assayed by a standardized sandwich enzyme-linked
immunosorbent assay (ELISA) method (R&D Systems,
Minneapolis, MN) in duplicate according to the manufac-
turer’s protocol. C-reactive protein (CRP) was also
checked at the clinical laboratory department, Far Eastern
Memorial Hospital. Each patients were checked these bio-
markers in the baseline status after enrollment. Ethical
approval from the hospital and informed consent from all
study subjects was obtained.
Covariates included age, sex, and the severity of respira-
tory disease, as well as other conditions associated with a
risk of pneumonia were recorded. We quantified the
severity of respiratory disease, independently of inhaled
corticosteroid use, by the number of dispensed prescrip-
tions for respiratory medications (beta-agonists, tiotro-
pium, theophylline). Another covariate was the number of
antibiotic prescriptions in the past year, although exclud-
ing the last 30 days because such recent antibiotic pre-
scriptions might have represented the initial therapy for
the pneumonia that resulted in hospitalization.
Categorical variables were compared by the chi-square
test, and continuous variables were compared by the Stu-
dent’s t test. A p value of less than 0.05 was considered
statistically significant. To identify risk factors for
pneumonia, multivariate analysis was performed with step-
wise logistic regression to calculate the odds ratio. A
Homer-Lemeshow goodnessof-fit test was used to help
determine if the model was fit to the data well. All statisti-
cal analyses were performed using SPSS for Windows
(SPSS 9.0 Statistical Package for Social Science, Inc., Chi-
cago IL).
Results
During the two-year study period, 274 patients were
diagnosed as having COPD. 223 patients were males and
51 were females, with a mean age of 63.2 years old. Other
demographic data such as lung function status, and
smoking history are summarized in Table 1. The average
baseline post-bronchodilator FEV1 was 46% of predicted.
Among these patients with lung function assessment, 47
(17.2%), 118 (43.1%), 71(25.9%) and 38 (13.8%) patients
had categorized as mild, moderate, severe, and very
severe lung function, respectively, according to the
GOLD classification [11].
According to the GOLD guidelines and clinical practice,
ICS were prescribed for patients with severe and, very
severe obstructive lung defects or frequent acute exacerba-
tion (125 (45.6%) ICS users). Pneumonia was confirmed in
29 patients via chest roentgenography interpretated by a
pulmonologists. The prevalence was 10.6%. The rate was
significantly higher in patients with ICS therapy (20/125,
16%) compared with those without ICS therapy (9/149,
6%) (p = 0.02). We stratified ICS therapy into medium
dose (500-999 ug/day fluticasone, 71 patients) and high
dose (1000 ug/day fluticasone and more, 54 patients) two
groups. There was no statistically difference in pneumonia
development between these two group (medium dose: 13/
71, 18.3% vs. high dose: 7/54, 12.9%, p = 0.47). (Table 2)
Therefore, the risk of pneumonia development increased
when using ICS therapy. There were four patients hospita-
lized for severe pneumonia. Among them, two patients
were treated with higher dose of ICS; and the other two
Table 1 Demographic characteristics of the patients with COPD
Variables COPD with ICS COPD without ICS p value
(n = 125) (n = 149)
Age 66.7 ± 24.8 69.1 ± 25.1 0.62
Gender (M/F) 117/8 136/13 0.68
smoking (pack-years) 25.3 ± 14.2 22.1 ± 11.9 0.49
Lung function
mild obstruction 0 47 (31.5%) < 0.01*
moderate obstruction 41 (32.8%) 77 (51.7%) 0.04*
severe obstruction 54 (43.2%) 17 (11.4%) < 0.01*
very severe obstruction 30 (24%) 8 (5.4%) < 0.01*
Pneumonia 20 (16%) 9 (6%) 0.02*
C-reactive Protein (CRP) (mg/L) 4.8 ± 1.9 4.3 ± 2.2 0.45
Placenta Growth Factor (PlGF)(pg/L) 53.5 ± 18 37.6 ± 18.3 < 0.01*
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no mortality due to pneumonia whether or not the
patients were hospitalized.
Serum biomarkers such as CRP and PlGF were also
measured. There was no difference in the average levels of
CRP in patients with ICS therapy (medium and high dose)
(4.8 ± 1.9 mg/L) compared with those without ICS therapy
(4.3 ± 2.2 mg/L, p = 0.45). However, PlGF levels were sig-
nificantly higher in patients using ICS (53.5 ± 18.1 pg/L)
than those without ICS (37.6 ± 18.3 mg/L, p < 0.01).
(Table 1) Patients with ICS treatment had worse obstruc-
tive lung function in clinical practice and guidelines
recommendations. In addition, there were no significant
differences in the levels of CRP and PlGF between the
COPD patients with the medium doses and those with
high doses of ICS (Table 2).
Multivariate analysis was performed to identify the risk
factors for developing pneumonia. After adjusting for sex,
age, medications, and smoking status, significant factors
including advanced COPD status (forced expiratory volume
in one second (FEV1) less than 40% of predicted) (odds
ratio (OR) 2.2, 95% confidence interval (CI): 1.1-6.9), ICS
prescription (odds ratio (OR) 2.4, 95% confidence interval
(CI): 1.3-8.7), the presence of diabetes mellitus (DM) (OR
2.6, 95% CI: 1.2-9.4) and PlGF level over 40 pg/L (OR 4.1,
95% CI: 1.5-9.9) (p < 0.01) were identified. (Table 3)
Discussion
The current guidelines for the management of COPD had
recommended that ICS combined with long-acting b-ago-
nist (LABA) could be prescribed for patients with severe
disease and/or frequent exacerbations [11]. The effective-
ness has been substantiated by recent publications demon-
strating that ICS/LABA combinations result in a decrease
frequency of acute exacerbations [8-10,15]. However, the
present study found that ICS-containing regimens were
associated with an increased risk of pneumonia, which
confirmed the findings with other studies [15-19]. There-
fore, this finding should raise the concern that ICS usage
would increase the morbidity and hospitalization due to
pneumonia in patients with COPD. Additionally, we
found that there was no difference in the incidence of
pneumonia between patients using medium or high doses
of ICS treatment and a novel biomarker with PlGF can
predict the development of pneumonia. Pneumonia devel-
opment did not seem to be associated with dosage of ICS.
The serum levels of PlGF seemed to reflect the severity of
airflow obstruction and lung parenchymal inflammatory
status in COPD patients.
The mechanism of an increased risk of pneumonia with
ICS therapy is unknown. It is generally recognized that
exacerbation of COPD are frequently associated with
infection. Thus, there is a paradox in that ICS-containing
regimens reduces the frequency of one infective complica-
tions of COPD (acute exacerbation), yet potentially
increases another (pneumonia). It is possible that ICS can
alter the local immune response and bacterial colonization
in the airway, because ICS regimens are very effective in
the management of the inflammation aspects of asthma
[33]. However, there have not been any reports of an
excess pneumonia incidence with ICS use in randomized
clinical trials in asthma patients. Corticosteroids have been
shown to be less effective in modulating neutrophil func-
tion (COPD) compared with other inflammatory cells
such as eosinophils or mast cells (asthma) [33]. Some stu-
dies, however, had documented that ICS regimens still
have the effect of reducing sputum neutrophilia in COPD
patients [34,35], perhaps due to decreasing neutrophil che-
motaxis [36].
In fact, clinicians still needs a good biomarker to reflect
the actual inflammatory responses in the lung. PlGF is a
50-kDa glycosylated dimeric protein sharing significant
sequence homology at the amino acid level with vascular
endothelial growth factor (VEGF) [37]. Two isoforms of
Table 2 Demographic characteristics of the patients with COPD using inhaled corticosteroids
Variables COPD with medium dose of ICS COPD with high dose of ICS p value
(n = 71) (n = 54)
Age 64.1 ± 25.2 68.5 ± 24.4 0.36
Gender (M/F) 66/5 51/3 0.48
smoking (pack-years) 26.4 ± 13.6 25.1 ± 11.1 0.41
Lung function
mild obstruction 0 0
moderate obstruction 31 (43.7%) 10 (18.5%) 0.04*
severe obstruction 31 (43.7%) 23 (42.6%) 0.90
very severe obstruction 9 (18.3%) 21 (31.5%) 0.01*
Pneumonia 13 (18.3%) 7 (12.9%) 0.47
Hospitalization 2 (2.8%) 2 (3.7%) 0.78
C-reactive Protein (CRP) (mg/L) 4.8 ± 2.4 4.7 ± 2.7 0.62
Placenta Growth Factor (PlGF)(pg/L) 49.2 ± 23.5 51.3 ± 20.8 0.56
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reported [38]. Like VEGF, PlGF exhibits mitogenic activ-
ity on cultured endothelial cells and induces angiogenesis
in vivo, and its effects on endothelial cells are the same as
to those of the potent classical angiogenic factors, such
as VEGF and fibroblast growth factor [39]. We have con-
firmed that PlGF were increased in serum and BAL fluids
of COPD patients, and correlated inversely with FEV1
[28]. In addition, bronchial cells can express PlGF via
proinflammatory cytokines stimulation and over-expres-
sion of PlGF would induce apoptosis. It could be a novel
biomarker to reflect the lung inflammation.
The symptoms of COPD acute exacerbations and pneu-
monia usually overlapped. This will cause the diagnosis
d i f f i c u l t ye s p e c i a l l yw i t h o u tl a b o r a t o r yd a t aa n dc h e s t
radiography. In this study, the diagnosis of pneumonia was
in fact confirmed by radiographic finding. So, the data
were more accuracy to elucidate the association between
the ICS-containing regimens and pneumonia risk.
COPD itself is associated with an increased risk of
pneumonia and the risk for pneumonia hospitalization is
greater for patients with severe underlying disease. Addi-
tionally, higher dose of ICS were more likely to be
prescribed to patients with more severe disease. To avoid
confounding by severity lung function status, Ernst and
collagens had reported that FEV1 severity were unlikely
association with both likelihood of pneumonia or ICS
prescription [40]. Several studies [15-19,41] were similar
to our data that ICS regimen was the independent risk
factor for an excess risk of pneumonia. Additionally,
advanced COPD status (FEV1 less than 40% of predicted)
was also an independent risk factor in our study. There
seemed to be not correlation between two factors in sta-
tistical analysis. Clinicians should remain vigilant for the
development of pneumonia with ICS therapy because the
signs and symptoms of pneumonia closely mimic those
of COPD exacerbation. Fortunately, all of these and our
data had shown that any increase in pneumonia events
with an ICS- containing COPD regimen dose not lead to
increased pneumonia mortality.
By multivariate analysis, risk factors for pneumonia also
included DM, and higher levels of PlGF (> 40 pg/dl).
Hyperglycemia causes impairment in immune response
and depresses neutrophil chemotaxis, phagocytosis, intra-
cellular bacteriocidal activity, opsonization and cell-
mediated immunity [42]. It is reasonable that patients with
Table 3 Multi-variate analysis of risk factors for pneumonia in patients with chronic obstructive pulmonary disease
Variables No. of patients No. of pneumonia (%) Univariate analysis Multivariate analysis
Age 128
< 60 years 146 14 (10.9) 0.5 (0.1-5.7)
≥ 60 years 15 (10.3)
Smoking (pack-years) 157
< 15 117 16 (10.2) 0.8 (0.5-4.3)
≥ 15 13 (11.1)
Serum CRP (mg/L) 163
< 4.0 111 16 (9.8) 1.2 (0.6-6.1)
≥ 4.0 13 (11.7)
Body mass index (BMI)
< 18 146 17 (11.6) 0.8 (0.4-6.7)
≥ 18 128 12 (9.4)
COPD status 75 2.5 (1.1-10.4)**
Advanced (FEV1< 40%) 199 12 (16) 2.2 (1.1-6.9)**
Non-advanced (FEV1 ≥ 40%) 17 (8.5)
ICS prescription 149 2.6 (1.4-8.9)* 2.4 (1.3-8.7)*
No 125 9 (6%)
Yes 20 (16%)
Serum PlGF (pg/L) 138 4.8 (1.3-11.2)* 4.1 (1.5-9.9)**
< 40 136 8 (5.8)
≥ 40 21 (15.4)
DM 127 2.3 (1.1-8.9)**
No 147 11 (8.6) 2.6 (1.4-10.5)**
Yes 18 (12.2)
*p < 0.05; **p < 0.01.
CRP: C-reactive protein; FEV1: forced expiratory volume in one second; PlGF: placenta growth factor; DM: diabetes mellitus.
All values are shown as mean ± standard deviation.
*Indicates a statistically significant difference between groups (p < 0.05).
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which was easily infected by microorganisms. Moreover, a
recent data showed that COPD patients with DM co-mor-
bidity had trend to have prolonged length of hospital stay
and increases risk of death in acute exacerbation [43].
Elevated PlGF expression had harmful effects in lung
epithelial cells and inversely correlated to lung function
status in patients with COPD [28]. The expression of PlGF
in COPD results from the stimulation of pro-inflammatory
mediators such as tumor necrosis factor-a (TNF-a), Inter-
leukin-8. Therefore, higher PlGF levels imply more inflam-
matory processes in the lung parenchyma, which prone to
acute exacerbations or the development of pneumonia. It
should be addressed that PlGF expression was not only
associated with lung function severity but also an indepen-
dent risk factor for predicting pneumonia development.
Besides, we also found that PlGF levels were more sensi-
tive in the prediction the pneumonia (or airway inflamma-
tion) than CRP. CRP has been shown to be a reliable
biomarker for COPD in systemic inflammation responses
and cardiovascular events [44], however, it is not good
marker for predicting pneumonia in COPD patients with
ICS treatment. Further studies should be performed and
to elucidate whether PlGF expression can reflect the sys-
temic inflammation response in COPD.
Our study is limited by its non-randomized study and
relatively small sample size. So, we could not determine
that the dose dependence of ICS was associated with the
risk of pneumonia development. Further prospective,
randomized studies with larger populations and more
laboratory investigations should be conducted to eluci-
date the mechanism for ICS treatment and pneumonia in
COPD patients and more reliable bio-markers to predict
the important issue.
Conclusions
In conclusion, ICS therapy in patients with COPD
increased the risk of pneumonia, which was not depen-
dent on the doses of ICS. Clinicians should closely moni-
tor the clinical symptoms and signs in COPD patients
with ICS therapy to detect the development of pneumo-
nia and administer antibiotics treatment in a timely man-
ner. Additionally, advanced COPD status, DM and
elevated PlGF level were independent risk factors for
pneumonia development. PlGF was a novel bio-marker
to predict the pneumonia status for COPD patients with
ICS therapy.
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